rs757081 — NUCB2 Gln338Glu (Q338E)

NUCB2 Gln338Glu — The Nesfatin-1 Variant Linking Appetite, Sleep, and Metabolic Risk

Nucleobindin-2 (NUCB2), encoded by the NUCB2 gene on chromosome 11, is not itself a signaling peptide — it is a precursor protein. After translation, it is cleaved by prohormone convertases¹¹ prohormone convertases
Enzymes that cut precursor proteins at specific sites to release active peptide hormones — the same family that processes insulin, glucagon, and opioids into three fragments, of which the N-terminal fragment, nesfatin-1, is the biologically active neuropeptide. Nesfatin-1 is produced primarily in hypothalamic nuclei²² hypothalamic nuclei
The arcuate, paraventricular, and lateral hypothalamic nuclei — the brain's master appetite and energy control regions and is also expressed in the brainstem, adipose tissue, pancreatic beta cells, and gut. It acts via melanocortin MC3/MC4 receptors and the corticotropin-releasing factor receptor 2 (CRF2), suppressing food intake in a leptin-independent manner — meaning it works even in obesity states where leptin resistance has developed.

The rs757081 variant (c.1012C>G) changes codon 338 of the NUCB2 protein from glutamine (Gln, Q) to glutamic acid (Glu, E) — a conservative substitution that nonetheless falls within the processed nesfatin-1 peptide region. Individuals carrying the reference C allele have the Gln338 form, which is associated with higher adiposity risk; those with the G allele (Glu338) show lower obesity rates and reduced circulating nesfatin-1 in some contexts. About 46% of people globally are CC homozygotes, 45% carry one G allele, and 10% are GG homozygotes.

The Mechanism

The Q338E substitution introduces a negatively charged glutamate at a position that in wild-type carries a neutral glutamine. Exactly how this alters nesfatin-1 function is not fully resolved at the molecular level, but the epidemiological consequence is consistent: the C allele (Gln338) associates with higher body adiposity and lower protective nesfatin-1 protein levels in metabolically stressed states. The PCOS study by Taskin et al.³³ PCOS study by Taskin et al.
Taskin MI et al. NUCB2 gene polymorphism and its relationship with nesfatin-1 levels in PCOS. Gynecol Endocrinol, 2016 found that obese women with CC or CG genotypes had significantly lower circulating nesfatin-1 than those with GG, suggesting the C allele produces either less stable or less secreted nesfatin-1 protein, compounding the already-reduced nesfatin-1 observed in obesity.

Beyond appetite and weight, nesfatin-1 participates in cardiovascular regulation. A genome-wide association study of blood pressure in 321,262 individuals⁴⁴ A genome-wide association study of blood pressure in 321,262 individuals
Hoffmann TJ et al. Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation. Nature Genetics, 2017 identified rs757081 as a significant blood pressure locus (p=5×10⁻¹¹ for systolic BP), with the C allele associated with modestly lower systolic blood pressure — a paradoxical finding given the C allele's adiposity risk, likely reflecting the complex pleiotropic effects of nesfatin-1 across vascular, renal, and central nervous system targets.

The Evidence

Obesity and adiposity. The foundational genetics study by Zegers et al.⁵⁵ Zegers et al.
Zegers D et al. Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men. Mol Genet Metab, 2011 genotyped 1,049 obese and 315 normal-weight Caucasian subjects and found that rs757081 (along with rs1330 and rs214101) was associated with obesity protection specifically in males, suggesting a sex-dependent role for NUCB2 in energy homeostasis.

Chen et al. (2013)⁶⁶ Chen et al. (2013)
Chen YY et al. The association of a nucleobindin 2 gene (NUCB2) variant with childhood adiposity. Gene, 2013 confirmed the signal in 526 severely obese children and 774 controls across Singapore and Chinese cohorts. The GG genotype was protective against obesity; the C allele carried an OR of 1.57 (95% CI 1.17–2.10) for adiposity risk in the discovery cohort and OR 1.69 (95% CI 1.12–2.55) in replication. Higher birth weight diminished this protective effect in GG children — a gene-environment interaction suggesting that early nutritional exposure modulates how the NUCB2 genotype affects later adiposity risk.

Nesfatin-1 levels and cardiometabolic markers. In 60 PCOS patients and 26 controls⁷⁷ 60 PCOS patients and 26 controls
Taskin MI et al. NUCB2 gene polymorphism and its relationship with nesfatin-1 levels in PCOS. Gynecol Endocrinol, 2016, nesfatin-1 levels were lower in obese PCOS patients than non-obese or healthy controls (p<0.001), and CC/CG genotypes were associated with lower nesfatin-1 than GG. Nesfatin-1 was negatively correlated with BMI, waist circumference, fasting insulin, HOMA-IR, and triglycerides — confirming its role as a cardiometabolic protective factor whose deficiency is compounded in both obesity and the CC genotype state.

Sleep and nesfatin-1. The genetic SNP has not yet been directly studied in sleep GWAS, but the functional biology of nesfatin-1 is well-characterized in sleep regulation. Vas et al. (2013, PLoS One)⁸⁸ Vas et al. (2013, PLoS One)
Vas S et al. Nesfatin-1/NUCB2 as a potential new element of sleep regulation in rats. PLoS One, 2013 showed that central administration of nesfatin-1 reduces REM sleep and increases wakefulness in rats. Following 72-hour REM sleep deprivation, hypothalamic nesfatin-1 expression (both mRNA and protein) decreased; during subsequent recovery sleep, nesfatin neurons showed enhanced Fos expression, indicating activation during sleep rebound. This bidirectional relationship establishes nesfatin-1 as a sleep-wake regulatory signal, not merely an appetite factor.

In obstructive sleep apnea patients⁹⁹ In obstructive sleep apnea patients
Shen P et al. Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome. Sleep Breath, 2015, nesfatin-1 levels were significantly lower than in healthy controls and inversely correlated with apnea-hypopnea index severity, independent of BMI. This connects the nesfatin-1 deficiency state — which the CC genotype partially produces — to worse sleep-disordered breathing severity.

Practical Implications

For CC homozygotes, the key action areas are meal timing, satiety monitoring, and awareness of sleep apnea risk. Since the CC genotype is associated with lower effective nesfatin-1 signaling, the natural satiety brake that nesfatin-1 provides may be attenuated. Dietary patterns that naturally boost hypothalamic nesfatin-1 signaling (notably protein-rich meals, which stimulate NUCB2 secretion from gut enteroendocrine cells and the brainstem) may partially compensate.

For CG heterozygotes, the risk is intermediate and the most important action is awareness — monitoring weight trends and recognizing that appetite regulation at the nesfatin-1 pathway level may be partially impaired.

The blood pressure association (C allele with lower SBP) may appear protective, but it is likely a downstream consequence of lower overall nesfatin-1 activity rather than a primary cardiovascular benefit — the metabolic tradeoffs outweigh any modest pressure-lowering effect.

Interactions

NUCB2 rs757081 has been studied alongside rs1330 and rs214101 in the same gene; these three SNPs may act as a haplotype affecting NUCB2 expression or protein processing efficiency. Research in obese males found that all three variants jointly associated with obesity protection, suggesting the full NUCB2 locus should eventually be assessed as a haplotype rather than individual SNPs.

Functionally, nesfatin-1 operates in the same hypothalamic circuits as leptin, ghrelin, and melanocortin peptides. Individuals who carry both NUCB2 risk variants and variants in the leptin receptor (LEPR) or MC4R (melanocortin-4 receptor) genes may have compounded appetite dysregulation through the nesfatin-1 and leptin pathways.